AstraZeneca Signs a Worldwide Development and Distribution Agreement with Oxford University for Vaccine Against COVID-19

AstraZeneca Signs a Worldwide Development and Distribution Agreement with Oxford University for Vaccine Against COVID-19

Shots:

  • The collaboration will bring Oxford’s recombinant adenovirus vaccine, ChAdOx1 nCoV-19 to the patients and will enable AstraZeneca to be responsible for the development and WW manufacturing and distribution of the vaccine
  • The alliance will combine Oxford’s expertise in vaccinology and AstraZeneca’s global development, manufacturing and distribution capabilities to combat the pandemic
  • ChAdOx1 is based on adenoviral vector technology and has entered P-I clinical study last week to evaluate its safety and efficacy in healthy volunteers aged 18-55yrs., across five centers in Southern England with its anticipated results in next month and the expected advancement to late-stage studies by the middle of the year

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: Sky News

Related News: Oxford Biomedica Joins Consortium to Develop ChAdOx1 nCov-19 for COVID-19